Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study - Wikidata - wikimedia - TriplyDB

Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study

Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study

http://www.wikidata.org/entity/Q33931754

about

Data quality of the monoclonal gammopathy of undetermined significance diagnosis in a hospital registry.Management of the adverse effects of lenalidomide in multiple myeloma.Acquired immune-mediated thrombophilia in lymphoproliferative disorders.Venous thromboembolism in cancer patients.The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2).A rare case of pylephlebitis after colonic polypectomy.Risk of site-specific cancer in incident venous thromboembolism: a population-based study Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study Neoplastic and non-neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study Approach to chemotherapy-associated thrombosis.Thrombosis is associated with inferior survival in multiple myeloma.Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study Monoclonal gammopathy of undetermined significance associated with blue finger syndrome Precursors to lymphoproliferative malignancies.The Incidence of Senile Cataract and Glaucoma is Increased in Patients with Plasma Cell Dyscrasias: Etiologic Implications.Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).The independent association of mean platelet volume with overall survival in multiple myeloma.Thrombotic complications in multiple myeloma: a report of three cases and review of the literature.Thrombosis in multiple myeloma (MM).Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians.Thromboembolic risk in hematological malignancies.The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma.Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.Pylephlebitis After Colonic Polypectomy Causing Fever and Abdominal Pain.Familial risks of unusual forms of venous thrombosis: a nationwide epidemiological study in Sweden.Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.Risk of stroke in patients with newly diagnosed multiple myeloma: a retrospective cohort study.Assessment of oxidative/nitrative modifications of plasma proteins, selected ROTEM parameters and kinetics of fibrinogen polymerization in patients with multiple myeloma at diagnosis.How I manage monoclonal gammopathy of undetermined significance.Hemorheological parameters in Monoclonal Gammopathy of Undetermined Significance (MGUS).Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma.Guidelines on the diagnosis and management of Waldenström macroglobulinaemia.Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma.Retrospective study of the incidence and patterns of arterial and venous thrombosis in Chinese versus African American patients with multiple myeloma.Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma

P2860

Q30665280-95F6B86B-F4CD-4508-988C-B3840375C984 Q33394632-15364F1F-A926-4854-B777-DF6929C5C2E8 Q33396280-A166435D-475A-49A0-84AC-16EF1D21AEE9 Q33419213-93A69B6B-CDAF-4324-928E-67199E692A9F Q33695919-9EE146A9-EA7F-4CD0-A301-1AFAB41C2A7E Q33749676-EB4E9087-F10D-4775-A2AC-455D825D4407 Q33777286-C272E960-AD9D-452A-B0FC-F8C496B9BB21 Q35118211-8A14A9DC-2581-4FF9-B104-60AEC285BAF0 Q36006375-D5E9C8BB-F381-4EA3-AE59-B46A220CA108 Q36037568-EAC80F17-9221-443F-91D6-8F99A17AA0AD Q36208099-7F07676C-564C-416C-A7D7-135FE12963EF Q36304793-A689565B-D68D-4C9A-92EC-A62E1B0E1F73 Q36366986-8246C4CC-B65D-461C-8F33-7DF82EF6EC1B Q36382493-D09333E1-46C2-4CB5-A0B2-5616868B63F8 Q36703424-AA7D7ED5-D1C6-4FAB-9098-628414C0822F Q36739877-9BCB0D4E-FB5B-4A84-BA97-448740C0679E Q37027418-896CDCCB-2EEF-4EA3-8A7A-3F5CF3B2B616 Q37582168-CD298385-3B1C-4444-802A-E6BACBCBE8D7 Q37641824-0264562F-FFAE-4513-8F12-C487CC90B5C5 Q37929631-FB60238E-AAC1-4547-9164-3CDD5BE9A171 Q38003019-054B481A-C8C3-49BE-906C-E7B5BED82A15 Q38114487-25E02451-07C9-4283-A290-7769B776BA62 Q38287304-BE110720-9BBB-4D50-98EC-58FA004FBEAC Q38714291-C4C7CB1F-BCD4-4FB8-9AF6-A7A52467F614 Q38783950-96E6ED52-E151-485B-9DAF-C34522679050 Q38921614-5AEE857E-4EF2-4587-8931-F6BF2277A76B Q39138108-43A2C4F7-90CF-43FD-9216-1A68F7571281 Q40148099-58FF21DF-6BEA-4B8F-AAC5-6F8BE76355FC Q45852873-7F803AE7-DAB8-43CF-BC93-5334C91A89B2 Q47642719-BF002C06-25A0-46F7-BEF0-44FD769CA52B Q48044631-5E9D5399-D9A9-4122-A4F8-DC073C544D46 Q48189074-A0A146F3-6BB8-49AA-AEF4-2C82C25E3158 Q48221793-FC38FC35-BEBC-4227-94E6-1CA32FB1EFB4 Q50075149-4BFF37BA-97A3-4E56-9046-873AA3C5B8A8 Q51022318-8933849F-BAB0-4CCB-867A-85340043E6EF Q52840250-60D4D595-D74D-44D2-A283-2BA0C69ED26D Q53091304-9DE70F12-6CAE-42BA-AD79-A94B5D018C61 Q53774591-635F374C-2B63-42FA-8060-57CDEF4C7770 Q57300330-4062DF97-A7CE-47B8-81BC-A6883B65829D Q57489994-FA0814D0-B9A0-4C3E-83DB-C025FF486AB6

P2860

Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study

http://www.wikidata.org/entity/Q33931754

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Arterial and venous thrombosis ...... loma: a population-based study

@ast

Arterial and venous thrombosis ...... loma: a population-based study

@en

type

label

Arterial and venous thrombosis ...... loma: a population-based study

@ast

Arterial and venous thrombosis ...... loma: a population-based study

@en

prefLabel

Arterial and venous thrombosis ...... loma: a population-based study

@ast

Arterial and venous thrombosis ...... loma: a population-based study

@en

P1433

Q33931754-92254B58-F9CE-42FC-B541-91CB1768092C

P1476

Q33931754-1522C9B1-B50D-4BF3-8C91-21A4504E3B77

P2093

Q33931754-4C523D51-AF23-40DC-BB55-6EE83569EA25

Q33931754-51C4770C-95F7-4E0E-953A-4322B9862055

Q33931754-70945E94-E2D4-4ADB-B3ED-72CD3AF0F9D9

Q33931754-A14FAE00-5729-4ED8-866E-068F0F6A6A65

Q33931754-B9199B24-08F9-4A2A-9F09-49EE2E32EA9C

Q33931754-BE3A56F1-1AE8-4DBE-BC53-5550555952F5

Q33931754-C1D1F2AF-D8A9-4E06-A298-DB38DFE1C134

Q33931754-CCB15E29-8903-42E4-B5FE-A49A8005AFF9

Q33931754-F85FE3FB-1A5D-4207-877C-6A082020F3ED

P2860

Q33931754-04036384-2893-428D-AD6D-0248411DC516

Q33931754-0C867D91-BA15-469B-AE52-BC54FFC841D1

Q33931754-0D46D699-D3D8-4964-A55C-2F5AC90EE7D9

Q33931754-0DBE2DD0-5C36-492E-8318-5861815A34C7

Q33931754-233A76C8-A3C2-449D-A57F-346E0F3971A7

Q33931754-23F68E44-A150-4001-856F-79DB0A786F26

Q33931754-2D22E56A-CF52-47C7-AA03-FCB35AD460CC

Q33931754-2E2B29A5-98DF-4F5E-B6BF-0EF97A4B606A

Q33931754-30016821-98BB-4B09-AA92-C97F051C5B2A

Q33931754-3410E2FB-6EB4-4EDF-8534-16750C268E7D

P304

Q33931754-466CE4E3-B130-4A82-B2CE-2A51B94D7D9A

P31

Q33931754-42054CB2-5A30-4211-B20B-3F0E318FE7D1

P356

Q33931754-CC60966C-DE49-4E64-8A7C-74E7FE3E07EF

P407

Q33931754-BDF3CFE7-1F67-42F9-8371-4CF44C114976

P433

Q33931754-B22C1730-CBAF-4216-97E0-988ED3408C2C

P478

Q33931754-A929556B-E212-4DF9-9412-B8D09F46B511

P50

Q33931754-0D02B558-BA61-46BE-B638-9EDED79C6D9D

P577

Q33931754-20C4516F-ED1F-40EB-BAB3-BCB8E5DDCDB2

P5875

Q33931754-4C9073C5-AE20-464B-99FD-4BDACB50B03F

P698

Q33931754-6D728D4D-E807-4D24-BE6E-5147805586FA

P921

Q33931754-02AE4ACF-1B63-41C9-94DF-507189E50EC3

P932

Q33931754-A16FDFB3-DB25-4DDC-89AB-41D74A6ED0EF

P356

BLOOD-2009-11-252072

P1433

P1476

Arterial and venous thrombosis ...... loma: a population-based study

@en

P2093

Anders Wahlin

http://www.w3.org/2001/XMLSchema#string

Cecilie Blimark

http://www.w3.org/2001/XMLSchema#string

Ingemar Turesson

http://www.w3.org/2001/XMLSchema#string

Lynn R Goldin

http://www.w3.org/2001/XMLSchema#string

Magnus Björkholm

http://www.w3.org/2001/XMLSchema#string

Ruth M Pfeiffer

http://www.w3.org/2001/XMLSchema#string

Sam Schulman

http://www.w3.org/2001/XMLSchema#string

Sigurdur Y Kristinsson

http://www.w3.org/2001/XMLSchema#string

Ulf-Henrik Mellqvist

http://www.w3.org/2001/XMLSchema#string

P2860

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma

Arterial thrombosis in four patients treated with thalidomide

Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

Thalidomide causes platelet activation, which can be abrogated by aspirin

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden

Thalidomide and rituximab in Waldenstrom macroglobulinemia

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

P304

4991-4998

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-11-252072

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42345098

http://www.w3.org/2001/XMLSchema#string

P698

20299513

http://www.w3.org/2001/XMLSchema#string

P921

P932

2890150

http://www.w3.org/2001/XMLSchema#string